ThromboGenics creates new company around pediatric brain tumor candidate
This article was originally published in Scrip
Following up on a decision first mentioned in an August 2014 business update, ThromboGenics has spun out a new company called Oncurious to develop the early clinical-stage oncology candidate TB-403. VIB, a Belgian life sciences institute, is also a partner in the new venture, and it is hoped that access to basic research at VIB will allow Oncurious to go on to build an oncology pipeline behind TB-403. ThromboGenics will be the majority shareholder.